ArticleJournal of neuro-oncology2026
Application of multidimensional cognitive training in the early postoperative period for glioma patients with cognitive impairment.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06327048 (Application of Cognitive Training Based on Remind Strategy in Glioma Patients With Cognitive Impairment), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Application of Cognitive Training Based on Remind Strategy in Glioma Patients With Cognitive Impairment
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeTo investigate the effects of a Multidimensional Cognitive Training (MCT) program on cognitive function, quality of life, and anxiety, depression symptoms among glioma patients experiencing cognitive impairment.
methodsA single-center, assessor-blinded, non-randomized controlled trial was conducted from January 2024 to January 2025 among glioma patients with cognitive impairment admitted to the neurosurgery department of a tertiary hospital in Lanzhou. Eligible participants were assigned to an intervention group (MCT plus standard rehabilitation care) or a control group (standard rehabilitation care only) based on their hospital ward. The MCT program was developed through expert consensus. Cognitive function (Montreal Cognitive Assessment [MoCA]), health-related quality of life (EORTC QLQ-C30), anxiety (Self-Rating Anxiety Scale [SAS]), and depression (Self-Rating Depression Scale [SDS]) were measured at baseline (T1), 4 weeks (T2), and 12 weeks (T3). Data were analyzed using repeated-measures ANOVA and generalized estimating equations.
resultsSixty-nine patients completed the study (intervention group: n = 36; control group: n = 33), with no significant baseline differences. Compared with controls, the intervention group showed greater gains in global cognitive function (MoCA: time × group interaction, p < 0.001; 12-week difference, p = 0.001) and specific cognitive domains (attention, language, memory, and orientation; all p < 0.05). Anxiety and depression also decreased significantly (SAS: interaction, p < 0.001; SDS: interaction, p < 0.01; between-group differences at 4 and 12 weeks, p < 0.05). Health-related quality of life (QLQ-C30: time × group interaction, p = 0.002; between-group difference at 12 weeks, p = 0.035).
conclusionMCT enhanced cognitive function, reduced anxiety and depression, and improved quality of life in glioma patients with cognitive impairment, likely through psychological regulation, environmental adaptation, and cognitive remodeling.
trial registrationThis study was registered at ClinicalTrials.gov (Identifier: NCT06327048) February 29, 2024. The trial was retrospectively registered.
Indexed as
Identifiers
42043588What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.